Departments of Outcomes Research.
Department of Anesthesiology, Allegheny Health Network, Pittsburgh, PA.
J Neurosurg Anesthesiol. 2022 Oct 1;34(4):401-406. doi: 10.1097/ANA.0000000000000777. Epub 2021 May 13.
Inhibition of the renin-angiotensin-aldosterone pathways reduces blood pressure and proliferation of vascular smooth muscles and may therefore reduce the risk of stroke. We tested the hypothesis that patients taking angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for at least 6 months have fewer postoperative strokes after non-neurological, noncarotid, and noncardiac surgeries than those who do not.
We considered adults who had noncardiac surgery at the Cleveland Clinic between January 2005 and December 2017. After excluding neurological and carotid surgeries, we assessed the confounder-adjusted association between chronic use of ACEIs/ARBs (during 6 preoperative months) and the incidence of postoperative stroke using logistic regression models.
Postoperative strokes occurred in 0.26% (27/10,449) of patients who were chronic ACEI/ARBs users and in 0.18% (112/62,771) of those who were not. There was no significant association between ACEI/ARB use and postoperative stroke, with an adjusted odds ratio of 1.15 (95% confidence interval [CI]: 0.91-1.44; P =0.24). Secondarily, there was no association between exposures to ACEIs and postoperative stroke, versus no such exposure (adjusted odds ratio 0.88, 95% CI: 0.65-1.19; P =0.33). Similarly, there was no association between exposure to ARBs and postoperative stroke, versus no such exposure (adjusted odds ratio 1.05, 95% CI: 0.75-1.48; P =0.75).
We did not detect an effect of chronic ACEI/ARB use on postoperative strokes in patients who had non-neurological, noncarotid and noncardiac surgery; however, power was extremely limited.
抑制肾素-血管紧张素-醛固酮途径可降低血压和血管平滑肌的增殖,因此可能降低中风风险。我们检验了这样一个假设,即至少使用血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)治疗 6 个月的患者,在接受非神经、非颈动脉和非心脏手术后,其术后中风的风险低于未使用的患者。
我们考虑了在克利夫兰诊所接受非心脏手术的成年人,时间范围为 2005 年 1 月至 2017 年 12 月。在排除神经和颈动脉手术后,我们使用逻辑回归模型评估了慢性使用 ACEI/ARB(在术前 6 个月期间)与术后中风发生率之间的混杂因素调整关联。
在慢性 ACEI/ARB 使用者中,术后中风发生率为 0.26%(27/10449),而非使用者为 0.18%(112/62771)。ACEI/ARB 使用与术后中风之间无显著关联,调整后的优势比为 1.15(95%置信区间[CI]:0.91-1.44;P=0.24)。其次,ACEI 暴露与术后中风之间无关联,而非 ACEI 暴露(调整后的优势比 0.88,95% CI:0.65-1.19;P=0.33)。同样,ARB 暴露与术后中风之间也无关联,而非 ARB 暴露(调整后的优势比 1.05,95% CI:0.75-1.48;P=0.75)。
我们没有发现慢性 ACEI/ARB 使用对接受非神经、非颈动脉和非心脏手术患者的术后中风有影响;然而,效力非常有限。